ProGenTech gains $21M in third venture round

ProGenTech, with operations in California and China, has pocketed $21 million in its third round of venture financing. The biotech company markets products for research and medical diagnostics and is developing a contamination free, cassette based automated nucleic acid purification system. Bay City Capital and DT Capital led the round. ProGenTech was founded by two engineers: Steve Yu and Jesus Ching. Yu will remain a director of the company and become its president and COO. Ching will become the chief scientific officer of ProGenTech.

- check out the press release

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.